Amgen announced that new preclinical data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 1-5, 2017, in Washington, D.C. These data provide insights into the potential of Amgen’s half-life optimized bispecific T cell engager (BiTE®) immunotherapy platform across different cancers, as well as the local and systemic immune effects from combining Amgen’s oncolytic virus with a CTLA-4 inhibitor.
Preclinical data from Amgen’s latest oncology candidate to enter clinical trials (AMG 176) will also be presented. AMG 176 is a potent, highly selective and reversible Mcl-1 inhibitor. A variety of studies have demonstrated that hematologic malignancies, such as multiple myeloma, acute myeloid leukemia and non-Hodgkin lymphoma, are particularly sensitive to Mcl-1 inhibition.
“AACR has always been an important meeting for sharing some of our latest advances in cancer research and 2017 is no exception. This year’s data underscores our commitment to Amgen’s evolving oncology portfolio and to the discovery and development of innovative new therapies,” said David Reese, M.D., senior vice president of Discovery Research (interim) and Translational Sciences at Amgen. “In addition to sharing new data for some of our more advanced compounds, we also look forward to sharing research around our first-in-class Mcl-1 inhibitor, a small molecule being investigated for its potential use in patients with hematologic malignancies for which there continues to be a need for new treatment options.”
Filed Under: Drug Discovery
